O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4 [published erratum appears in Mol Pharmacol 1995 Sep;48(3):568]

MV Relling, J Nemec, EG Schuetz, JD Schuetz, FJ Gonzalez and KR Korzekwa

Pharmaceutical Department, St. Jude Children's Research Hospital, Memphis, Tennessee 38105.

We previously demonstrated that O-demethylation of the pendant dimethoxyphenol ring of epipodophyllotoxins to produce their respective catechol metabolites is catalyzed by cytochrome(s) P450 in human liver microsomes. Our objective was to identify the specific human cytochrome(s) P450 responsible for catechol formation. Using a panel of prototypical substrates and inhibitors for specific cytochromes P450, we identified substrates for CYP3A4 (midazolam, erythromycin, cyclosporin, and dexamethasone) as inhibitors of catechol formation from both etoposide and teniposide. Dexamethasone inhibition was competitive, with Ki values of 60 and 45 microM for etoposide and teniposide, respectively. In 58 human livers, the correlation coefficients for teniposide catechol formation versus 1'- and 4- hydroxymidazolam formation were 80% and 85%, respectively; for etoposide catechol formation versus 1'- and 4-hydroxymidazolam formation r2 was 83% and 79%, respectively. Teniposide and etoposide catechol formation rates were also significantly correlated with immunodetectable CYP3A (r2 = 49% and 51%, respectively) and not with immunodetectable CYP1A2, 2E1, or 2C8. Finally, cDNAs for human CYP3A4, 3A5, 2A6, 2B6, 2C8, and 2C9 were functionally expressed in HepG2 cells, using a vaccinia viral vector. Teniposide and etoposide catechol formation was catalyzed primarily by 3A4 (15.4 and 40.9 pmol/pmol/hr, respectively) and to a lesser degree by 3A5 (1.94 and 11.3 pmol/pmol/hr, respectively), whereas there was no detectable O- demethylation of epipodophyllotoxins by 2A6, 2B6, 2C8, 2C9, or the control virus alone. Moreover, the relative activities of midazolam hydroxylation, compared with O-demethylation of epipodophyllotoxins, were similar for heterologously expressed 3A4 and for human liver microsomes. We conclude that catechol formation from teniposide and etoposide is primarily mediated by human CYP3A4, making these reactions susceptible to inhibition by prototypical 3A substrates and inhibitors.

Volume 45, Issue 2, pp. 352-358, 02/01/1994
Copyright © 1994 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				R. Obligacion, M. Murray, and I. Ramzan Drug-Metabolizing Enzymes and Transporters: Expression in the Human Prostate and Roles in Prostate Drug Disposition J Androl, March 1, 2006; 27(2): 138 - 150. [Full Text] [PDF]

				J. Ramirez, F. Innocenti, E. G. Schuetz, D. A. Flockhart, M. V. Relling, R. Santucci, and M. J. Ratain CYP2B6, CYP3A4, AND CYP2C19 ARE RESPONSIBLE FOR THE IN VITRO N-DEMETHYLATION OF MEPERIDINE IN HUMAN LIVER MICROSOMES Drug Metab. Dispos., September 1, 2004; 32(9): 930 - 936. [Abstract] [Full Text] [PDF]

				X. Zhuo, N. Zheng, C. A. Felix, and I. A. Blair KINETICS AND REGULATION OF CYTOCHROME P450-MEDIATED ETOPOSIDE METABOLISM Drug Metab. Dispos., September 1, 2004; 32(9): 993 - 1000. [Abstract] [Full Text] [PDF]

				N. Zheng, C. A. Felix, S. Pang, R. Boston, P. Moate, J. Scavuzzo, and I. A. Blair Plasma Etoposide Catechol Increases in Pediatric Patients Undergoing Multiple-Day Chemotherapy with Etoposide Clin. Cancer Res., May 1, 2004; 10(9): 2977 - 2985. [Abstract] [Full Text] [PDF]

				M. C. E. McFadyen, W. T. Melvin, and G. I. Murray Cytochrome P450 enzymes: Novel options for cancer therapeutics Mol. Cancer Ther., March 1, 2004; 3(3): 363 - 371. [Abstract] [Full Text]

				G. Ghannam, A. Takeda, T. Camarata, M. A. Moore, A. Viale, and N. R. Yaseen The Oncogene Nup98-HOXA9 Induces Gene Transcription in Myeloid Cells J. Biol. Chem., January 9, 2004; 279(2): 866 - 875. [Abstract] [Full Text] [PDF]

				S. Kishi, W. Yang, B. Boureau, S. Morand, S. Das, P. Chen, E. H. Cook, G. L. Rosner, E. Schuetz, C.-H. Pui, et al. Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia Blood, January 1, 2004; 103(1): 67 - 72. [Abstract] [Full Text] [PDF]

				Y. Watanabe, M. Nakajima, N. Ohashi, T. Kume, and T. Yokoi Glucuronidation of Etoposide in Human Liver Microsomes Is Specifically Catalyzed by UDP-Glucuronosyltransferase 1A1 Drug Metab. Dispos., May 1, 2003; 31(5): 589 - 595. [Abstract] [Full Text] [PDF]

				M. J. Edick, A. Gajjar, H. H. Mahmoud, M. E.C. van de Poll, P. L. Harrison, J. C. Panetta, G. K. Rivera, R. C. Ribeiro, J. T. Sandlund, J. M. Boyett, et al. Pharmacokinetics and Pharmacodynamics of Oral Etoposide in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia J. Clin. Oncol., April 1, 2003; 21(7): 1340 - 1346. [Abstract] [Full Text] [PDF]

				Y. S. Lin, A. L. S. Dowling, S. D. Quigley, F. M. Farin, J. Zhang, J. Lamba, E. G. Schuetz, and K. E. Thummel Co-Regulation of CYP3A4 and CYP3A5 and Contribution to Hepatic and Intestinal Midazolam Metabolism Mol. Pharmacol., July 1, 2002; 62(1): 162 - 172. [Abstract] [Full Text] [PDF]

				B. D. Lovett, L. L. Nigro, E. F. Rappaport, I. A. Blair, N. Osheroff, N. Zheng, M. D. Megonigal, W. R. Williams, P. C. Nowell, and C. A. Felix Near-precise interchromosomal recombination and functional DNA topoisomerase II cleavage sites at MLL and AF-4 genomic breakpoints in treatment-related acute lymphoblastic leukemia with t(4;11) translocation PNAS, August 1, 2001; (2001) 171309898. [Abstract] [Full Text] [PDF]

				D. Yao, S. Ding, B. Burchell, C. R. Wolf, and T. Friedberg Detoxication of Vinca Alkaloids by Human P450 CYP3A4-Mediated Metabolism: Implications for the Development of Drug Resistance J. Pharmacol. Exp. Ther., July 1, 2000; 294(1): 387 - 395. [Abstract] [Full Text]

				J. G. Blanco, P. L. Harrison, W. E. Evans, and M. V. Relling Human Cytochrome P450 Maximal Activities In Pediatric versus Adult Liver Drug Metab. Dispos., April 1, 2000; 28(4): 379 - 382. [Abstract] [Full Text]

				S.-i. Kuriya, S. Ohmori, M. Hino, I. Ishii, H. Nakamura, C. Senda, T. Igarashi, M. Kiuchi, and M. Kitada Identification of Cytochrome P-450 Isoform(s) Responsible for the Metabolism of Pimobendan in Human Liver Microsomes Drug Metab. Dispos., January 1, 2000; 28(1): 73 - 78. [Abstract] [Full Text]

				B. Goodwin, E. Hodgson, and C. Liddle The Orphan Human Pregnane X Receptor Mediates the Transcriptional Activation of CYP3A4 by Rifampicin through a Distal Enhancer Module Mol. Pharmacol., December 1, 1999; 56(6): 1329 - 1339. [Abstract] [Full Text]

				K. Hande, M. Messenger, J. Wagner, M. Krozely, and S. Kaul Inter- and Intrapatient Variability in Etoposide Kinetics with Oral and Intravenous Drug Administration Clin. Cancer Res., October 1, 1999; 5(10): 2742 - 2747. [Abstract] [Full Text] [PDF]

				T. Kawashiro, K. Yamashita, X.-J. Zhao, E. Koyama, M. Tani, K. Chiba, and T. Ishizaki A Study on the Metabolism of Etoposide and Possible Interactions with Antitumor or Supporting Agents by Human Liver Microsomes J. Pharmacol. Exp. Ther., September 1, 1998; 286(3): 1294 - 1300. [Abstract] [Full Text]

				V. Fischer, A. Rodríguez-Gascón, F. Heitz, R. Tynes, C. Hauck, D. Cohen, and A. E. M. Vickers The Multidrug Resistance Modulator Valspodar (PSC 833) Is Metabolized by Human Cytochrome P450 3A. Implications for Drug-Drug Interactions and Pharmacological Activity of the Main Metabolite Drug Metab. Dispos., August 1, 1998; 26(8): 802 - 811. [Abstract] [Full Text]

				Y. Zhang, X. Guo, E. T. Lin, and L. Z. Benet Overlapping Substrate Specificities of Cytochrome P450 3A and P-Glycoprotein for a Novel Cysteine Protease Inhibitor Drug Metab. Dispos., April 1, 1998; 26(4): 360 - 366. [Abstract] [Full Text]

				B. D. Lovett, L. Lo Nigro, E. F. Rappaport, I. A. Blair, N. Osheroff, N. Zheng, M. D. Megonigal, W. R. Williams, P. C. Nowell, and C. A. Felix Near-precise interchromosomal recombination and functional DNA topoisomerase II cleavage sites at MLL and AF-4 genomic breakpoints in treatment-related acute lymphoblastic leukemia with t(4;11) translocation PNAS, August 14, 2001; 98(17): 9802 - 9807. [Abstract] [Full Text] [PDF]